Therapeutic applications of DP2 antagonists
| DP2 antagonist | Route | Dose | Species | Experimental Model | Indication | Reference |
|---|---|---|---|---|---|---|
| mg/kg | ||||||
| AM 156 | Oral | 10 | Mouse | Smoke exposure | COPD | Stebbins et al., 2010 |
| Compound 23 | Oral | 10 | Mouse | Ovalbumin allergy | Allergic rhinitis | Stearns et al., 2009 |
| Compound A | Oral | 10 | Mouse | FITC-cutaneous allergy | Atopic dermatitis | Boehme et al., 2009 |
| Ramatroban | Oral | 5 | Mouse | Allergic (ovalbumin) eosinophilic airway inflammation | Asthma | Uller et al., 2007 |
| Ramatroban | Oral | 30 | Mouse | Cry J1-induced pollinosis | Allergic rhinitis | Nomiya et al., 2008 |
| TM-30089 | Oral | 5 | Mouse | Allergic (ovalbumin) eosinophilic airway inflammation | Asthma | Uller et al., 2007 |
AM 156, (2′-((cyclopropanecarbonylethylamino)methyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl)acetic acid; COPD, chronic obstructive pulmonary disease; FITC, fluorescein isothiocyanate.